Some detailed articles on specific MPN treatments are outlined below.
All MPNs
Polycythemia vera and Essential thrombocythemia
These include information about when to start treatment, and evidence on efficacy of Hydroxycarbamide (hydroxyurea) versus Interferon Alpha (pegasys).
- Final results from the large PROUD-PV trial and its extension CONTINUATION-PV (over 6 years)
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment, ‘Leukemia’, 2023 - Real-world treatments and thrombotic events in polycythemia vera patients in the USA, ‘Annals of Hematology’, 2023
- Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b, ‘Leukemia’, 2022
- Interferons in MPNs, a conversation with an MPN specialist, 2022 – excellent video, courtesy of MPN Advocacy and Education International.
- Interferon induced retinopathy, Continuing Education Activity, (National Library of Medicine), 2022
- Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations – for PV patients under 60 (Comprehensive summary of this article available courtesy of MPN-Hub) The Lancet, Haematology, 2022
- New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms, ‘Hemasphere’, 2021
- ‘Normal life expectancy for polycythemia vera patients is possible’‘, ‘Blood’, 2021
- Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival ‘Leukaemia’, 2021
- Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis, ‘Blood’, 2020
- Basis of Hematocrit Treatment Guideline for PV: Cardiovascular Events and the Intensity of Treatment in Polycythaemia Vera, ‘NEJM’, 2013
Myelofibrosis
- Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy, Leukemia and Lymphoma, 2023
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety, Journal of Hematology and Oncology, 2023
- Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: A modified Delphi panel consensus study, ‘Future Oncol’. 2023.
- Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany, Journal of Cancer Research and Clinical Oncology, 2023
- Momelotinib Long-Term Safety and Survival in Myelofibrosis: Integrated Analysis of Phase 3 Randomized-Controlled Trials, Blood Advances, 2023
- Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study, The Lancet, 2023
- Future of Jak inhibition in myelofibrosis, 2022 (detailed video discussion from MPN experts courtesy of MPN Hub)
- Evolving therapy of MPNs 2022 – video overview by Dr Ruben Mesa. Myelofibrosis specific information commences at 27.42 minutes
- A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study, Therapeutic Advances in Hematology, 2022
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia, Journal of Hematology and Oncology, 2022
- Momentum: Phase 3 randomized study of Momelotinib versus Danazol in symptomatic and anemic myelofibrosis patients previously treated with a Jak inhibitor, European Hematology Association Conference, 2022 – Oral presentation
- Defining disease modification in myelofibrosis in the era of targeted therapy, American Cancer Society Journals, 2022
- Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis, Blood Cancer Journal, 2021
Myelofibrosis Stem Cell Transplant information
- Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica. 2023
- Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms:
A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, AJH, 2023 - Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis, AJH, 2022
- Myelofibrosis Stem Cell Transplant (SCT) Timing Tool
- Survival following allogeneic transplant in patients with myelofibrosis
ALL MPNs
Management of MPN in pregnant patients
- Best practice recommendations for the management of MPN in pregnant patients, courtesy of MPN Hub, 2021
(Please note that these are not Australian guidelines and local Australian practices may differ.) - How interferon works in MPN patients, November 2022, courtesy of MPN Advocacy and Education International
This is a video presentation and Q and A session with Dr Gaby Hobbs, MPN specialist, Clinical Director of Leukemia Service at Massachusetts General Hospital and Assistant Professor at Harvard Medical School. This is wide-ranging and includes considerations physicians take into account about using interferon in pregnancy (35 mins in).
Possible future treatments via targeted therapies – may not yet be available in Australia
- Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial, ‘Journal of Clinical Oncology’, 2023
- Defining disease modification in myelofibrosis in the era of targeted therapy – American Cancer Society Journal, ‘Cancer’, 2022
- New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options – ‘Medicina’, 2021
